Molbio Diagnostics IPO to open on August 10, price band set at Rs 768-807

Molbio Diagnostics, a leading point-of-care molecular diagnostics company, is set to launch its initial public offering (IPO) on August 10, 2026, with a price band of Rs 768 to Rs 807 per share. The IPO, which will remain open for subscription until August 12, 2026, is expected to raise approximately Rs 939.70 crore.

The issue comprises a fresh issue of shares worth Rs 200 crore and an offer for sale (OFS) component amounting to Rs 739.70 crore. Under the OFS route, existing shareholders of the company will sell part of their holdings.

Among the key shareholders participating in the OFS, promoter entity Exxora Trading LLP will sell 18.11 lakh shares, valued at around Rs 146.15 crore. Corporate shareholder India Business Excellence Fund III will offer 10 lakh shares worth Rs 80.70 crore, while promoter shareholder Chandrasekhar Bhaskaran Nair will sell 12.21 lakh shares amounting to Rs 98.53 crore.


IPO timeline and key details
The Molbio Diagnostics IPO will open for investors on August 10, 2026, and close on August 12, 2026. The allotment basis is expected to be finalised on August 13, 2026, with the company likely to make its market debut on August 17, 2026, on both the NSE and BSE.

The IPO lot size has been fixed at 18 shares, meaning retail investors will need to invest a minimum of Rs 14,526 at the upper end of the price band.

Kotak Mahindra Capital Company is acting as the book-running lead manager for the issue, while KFin Technologies Ltd. has been appointed as the registrar.

How Molbio Diagnostics plans to use IPO funds
Molbio Diagnostics plans to utilise the IPO proceeds to expand its infrastructure and enhance its research and manufacturing capabilities. The total estimated utilisation of the IPO proceeds stands at Rs 205.93 crore.

A significant portion of the funds—around Rs 125.12 crore—will be invested in capital expenditure to develop a research and development facility, Centre of Excellence, and related office infrastructure.

The company will allocate the remaining Rs 80.81 crore towards the purchase of plant, machinery, and other equipment for its manufacturing facilities located in Goa and Visakhapatnam. The remaining funds will be used for general corporate purposes.

About Molbio Diagnostics
Established in October 2000, Molbio Diagnostics Ltd. is a global molecular diagnostics company focused on developing, manufacturing, and commercialising rapid diagnostic solutions for infectious and non-communicable diseases.

The company is best known for its proprietary Truenat platform, a portable, battery-operated PCR-based molecular diagnostic system designed to deliver accurate test results within an hour, particularly in resource-constrained healthcare environments.

Molbio offers testing solutions for more than 30 diseases through 43 diagnostic assays, covering critical areas such as tuberculosis, COVID-19, HIV, Hepatitis B and C, and HPV.

Beyond molecular diagnostics, the company has expanded into areas including radiology, digital pathology, and breast health screening through subsidiaries and strategic partnerships. Backed by strong research and development capabilities, Molbio continues to build its diagnostics product pipeline.

Strong financial performance ahead of IPO
Molbio Diagnostics has reported healthy financial growth ahead of its public issue. In FY26, the company’s total income increased by 42% year-on-year, rising to Rs 1,455 crore from Rs 1,027 crore in FY25. The company’s profitability also improved, with profit after tax (PAT) rising 18% to Rs 164 crore in FY26, compared with Rs 138.58 crore in the previous financial year.

With its focus on expanding diagnostic infrastructure, strengthening R&D capabilities, and scaling its global healthcare footprint, Molbio Diagnostics is entering the capital markets at a time when demand for rapid and accessible diagnostic solutions continues to grow.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)